Literature DB >> 12113106

Current epidemiological trends and surveillance issues in brain tumors.

F G Davis1, B J McCarthy.   

Abstract

The absence of an overall increase in incidence rates for all primary brain tumors since the 1950s argues against a recently introduced environmental tumorigen impacting these tumors. Historical increases in brain cancer mortality and incidence rates appear to be leveling off following the widespread introduction of CT and MRI scans, indicating that increases in overall rates of malignant tumors are likely to be an artifact of diagnosis and reporting issues. Further studies are needed to understand those tumor types with rates that do appear to be increasing among adults; specifically lymphomas, nerve sheath tumors, pituitary tumors and ependymomas. Patterns of incidence by race, ethnicity, socioeconomic status, and seasonal and regional variation would assist in directing relevant new research questions. Filling in the gap of information on patterns for prevalent, second primaries and metastatic tumors may be useful in understanding the public perception regarding brain tumor rates and would be a valuable addition to healthcare planning tools.

Entities:  

Mesh:

Year:  2001        PMID: 12113106     DOI: 10.1586/14737140.1.3.395

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  45 in total

1.  Brain tumours: incidence, survival, and aetiology.

Authors:  P A McKinney
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  LEF1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal.

Authors:  Xingchun Gao; Yajing Mi; Yue Ma; Weilin Jin
Journal:  Tumour Biol       Date:  2014-08-16

3.  Telomerase reverse transcriptase (TERT) rs2736100 polymorphism contributes to increased risk of glioma: evidence from a meta-analysis.

Authors:  Zesheng Peng; Daofeng Tian; Qianxue Chen; Shenqi Zhang; Baohui Liu; Baowei Ji
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.

Authors:  Zhumei Shi; Qiudan Chen; Chongyong Li; Lin Wang; Xu Qian; Chengfei Jiang; Xue Liu; Xiefeng Wang; Hai Li; Chunsheng Kang; Tao Jiang; Ling-Zhi Liu; Yongping You; Ning Liu; Bing-Hua Jiang
Journal:  Neuro Oncol       Date:  2014-05-25       Impact factor: 12.300

5.  Overexpression of NTPDase2 in gliomas promotes systemic inflammation and pulmonary injury.

Authors:  Elizandra Braganhol; Rafael F Zanin; Andressa Bernardi; Leticia S Bergamin; Angelica R Cappellari; Luis F Campesato; Fernanda B Morrone; Maria M Campos; João B Calixto; Maria Isabel A Edelweiss; Márcia R Wink; Jean Sévigny; Simon C Robson; Ana Maria O Battastini
Journal:  Purinergic Signal       Date:  2011-10-30       Impact factor: 3.765

6.  Downregulation of microRNA-124 predicts poor prognosis in glioma patients.

Authors:  Teng Chen; Xin-Yu Wang; Chao Li; Shu-Jun Xu
Journal:  Neurol Sci       Date:  2014-08-12       Impact factor: 3.307

7.  Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model.

Authors:  Jun Jin; Suh Hee Choi; Jung Eun Lee; Jin-Deok Joo; Jung Ho Han; Su-Young Park; Chae-Yong Kim
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

8.  miR-92b regulates glioma cells proliferation, migration, invasion, and apoptosis via PTEN/Akt signaling pathway.

Authors:  Hang Song; Yao Zhang; Na Liu; Chao Wan; Dongdong Zhang; Sheng Zhao; Yan Kong; Liudi Yuan
Journal:  J Physiol Biochem       Date:  2016-02-18       Impact factor: 4.158

9.  A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing.

Authors:  Dasong Hua; Fan Mo; Dong Ding; Lisa Li; Xu Han; Na Zhao; Gregory Foltz; Biaoyang Lin; Qing Lan; Qiang Huang
Journal:  OMICS       Date:  2012-12

10.  Incidence of first primary central nervous system tumors in California, 2001-2005.

Authors:  Monica Brown; Rudolph Schrot; Katrina Bauer; Deanna Letendre
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.